Through the promotion of skin health from the inside out, Prime Biome is designed to provide a risk-free and natural approach ...

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- The CrazyBulk line of products are designed as a legal and safer alternative to ...

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Louvain-la-Neuve, Belgium, April 18th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA ...

Safety Shot, Inc. (Nasdaq: SHOT) (the “Company” or “Safety Shot”), today announced that the record date for the spin-off and distribution of shares of common stock, par value $0.0001 per share, ...

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) Approval based on Phase 3 trials demonstrating Dupixent ...

Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) (“Hapbee” or the “Company”), the digital wellness technology company, announces that it anticipates a delay in the filing of the ...

Court-Approved Bidding Procedures 23andMe is requiring all bidders in the court-supervised marketing process to guaranty that they will comply with the Company’s privacy policies and applicable law.

Clenbuterol is one of the most popular choices for cutting, and for good reason—it’s incredibly effective at burning fat and boosting metabolism. Known for its thermogenic properties, Clenbuterol ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

Paris and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic ...